Cell and Gene Therapy CDMO Market Size & Growth Forecast 2027–2036, By Segments (Phase, Product Type, Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cell and Gene Therapy CDMO Market size was worth USD 6.2 billion in 2026 and is expected to grow at a 22.23% CAGR between 2027 and 2036, exceeding USD 46.15 billion by 2036. The industry revenue for 2027 is assessed at USD 7.36 billion.
Get more details on this report
Request Free Sample ReportCell and Gene Therapy CDMO Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 43.25% of the market in 2026, driven by established biopharma companies, advanced CDMO infrastructure, and integrated capabilities spanning development through commercial manufacturing.
- Asia Pacific is projected to expand at a 29.7% CAGR as outsourcing increases and regional CDMOs strengthen manufacturing capacity, process optimization, and clinical-scale production capabilities.
Segment Momentum
- The Pre-clinical phase accounted for 62.95% of the market in 2026, driven by high volumes of early-stage outsourcing for vector design, process development, analytical setup, and manufacturability before clinical progression.
- Gene-Modified Cell Therapy is expanding fastest because it combines cell processing with complex genetic modification, increasing demand for integrated CDMO capabilities that support specialized manufacturing and development workflows.
Market Expansion Drivers
- Expanding outsourcing demand due to complex GMP requirements and limited in-house capacity.
- Rising clinical trials and regulatory approvals accelerating advanced therapy manufacturing demand.
- Capacity expansion in viral vector production and CDMO consolidation strengthening supply chains.
Leading Market Participants
- Key companies in the cell and gene therapy CDMO market include Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (United States), Catalent, Inc. (United States), Samsung Biologics Co., Ltd. (South Korea), WuXi AppTec Co., Ltd. (China), AGC Biologics (Japan), Charles River Laboratories International, Inc. (United States), Cytiva (United States), Rentschler Biopharma SE (Germany), Fujifilm Diosynth Biotechnologies (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.2 billion
- 2027 Estimated Market Size: USD 7.36 billion.
- Projected Market Size: USD 46.15 billion by 2036
- Growth Forecast: 22.23% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Pre-clinical (Phase) | Cell Therapy (Product Type) | Oncology (Indication)
- Emerging Opportunity Segment: Clinical (Phase) | Gene-Modified Cell Therapy (Product Type) | Rare Diseases (Indication)
Market Growth Drivers and Industry Trends
Expanding outsourcing demand due to complex GMP requirements and limited in-house capacity
Complex manufacturing requirements and stringent GMP expectations are driving pharmaceutical and biotechnology developers toward specialized external manufacturing partners, strengthening the cell and gene therapy CDMO market growth. Cell and gene therapies require sophisticated production workflows, controlled processing environments, specialized quality systems, and extensive regulatory documentation, which can be difficult and costly to establish internally. Developers with limited manufacturing infrastructure can therefore rely on CDMOs for process development, technology transfer, analytical support, and commercial-scale production, allowing internal resources to remain focused on therapeutic development while accessing established technical capabilities and compliant manufacturing environments.
Rising clinical trials and regulatory approvals accelerating advanced therapy manufacturing demand
The increasing number of cell and gene therapy clinical programs, combined with regulatory progress for advanced therapies, will propel the cell and gene therapy CDMO market as developers require reliable manufacturing capacity throughout clinical development and commercialization. Advancing therapies must move through increasingly complex production and quality requirements as they progress from early-stage research into later clinical phases. This creates demand for specialized CDMO services covering process optimization, clinical material production, testing, and scalable manufacturing, while successful regulatory pathways can encourage developers to prepare production systems capable of meeting more demanding supply and quality requirements.
Capacity expansion in viral vector production and CDMO consolidation strengthening supply chains
Expansion of viral vector manufacturing capabilities is strengthening supply availability, while consolidation among specialized service providers is reshaping the cell and gene therapy CDMO market by creating broader technical and production networks. Viral vectors are essential components of many advanced therapy manufacturing processes, requiring specialized facilities, equipment, quality controls, and expertise. Increasing production capacity can help address manufacturing bottlenecks and support developers as programs advance through clinical stages, while consolidation can combine complementary capabilities across process development, vector manufacturing, analytical services, and other specialized operations within integrated service platforms.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding outsourcing demand due to complex GMP requirements and limited in-house capacity | 3.00% | High | North America, Europe | High | Near Term |
| Rising clinical trials and regulatory approvals accelerating advanced therapy manufacturing demand | 3.20% | High | North America, Europe, Asia Pacific | High | Near Term |
| Capacity expansion in viral vector production and CDMO consolidation strengthening supply chains | 2.70% | High | North America, Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America led the cell and gene therapy CDMO market with a 43.25% share in 2026, reflecting its advanced biotechnology ecosystem, established clinical development infrastructure, and strong concentration of specialized manufacturing capabilities. Demand for outsourced development and production is supported by the increasing complexity of cell and gene therapy processes, stringent quality requirements, and the need for scalable manufacturing platforms. The region also benefits from substantial research activity, specialized workforce capabilities, and sophisticated supply chains that support process development, viral vector production, analytical testing, and commercial manufacturing.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market as governments, healthcare institutions, and biotechnology organizations strengthen capabilities for advanced therapeutic development and manufacturing. Increasing investment in biopharmaceutical infrastructure, expanding clinical research activity, and growing demand for localized production are encouraging greater use of specialized CDMO services. The region's developing biotechnology talent pool and improving regulatory and manufacturing environments are further supporting the establishment of capabilities for cell processing, gene delivery technologies, analytical development, and other complex production requirements.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Process Development ExpertiseGermany strengthens its cell and gene therapy CDMO capabilities through advanced bioprocess development and high manufacturing standards. Companies prioritize technology integration, quality assurance, and flexible production services for innovative therapy developers.
France 🇫🇷
Clinical Manufacturing NetworkFrance supports cell and gene therapy CDMO growth through integrated clinical manufacturing and research collaboration. Companies emphasize compliant production, technology transfer capabilities, and specialized expertise for advanced therapeutic products.
Italy 🇮🇹
Specialized Production ServicesItaly develops specialized CDMO services for cell and gene therapies by strengthening GMP manufacturing and process development expertise. Providers focus on customized project support, quality management, and partnerships with biotechnology innovators.
Japan 🇯🇵
Regenerative Medicine SupportJapan advances cell and gene therapy CDMO services through its strong regenerative medicine ecosystem. Contract manufacturers focus on robust quality systems, specialized manufacturing processes, and partnerships supporting clinical translation and commercialization.
South Korea 🇰🇷
Biomanufacturing Capacity BuildoutSouth Korea expands cell and gene therapy CDMO operations through investments in modern biomanufacturing infrastructure. Providers strengthen process scalability, analytical capabilities, and international compliance to attract global therapy developers.
United States 🇺🇸
Advanced Therapy ManufacturingThe U.S. cell and gene therapy CDMO market continues expanding alongside a strong pipeline of advanced therapies. Service providers invest in scalable manufacturing platforms, regulatory expertise, and specialized facilities that support commercial and clinical production requirements.
Segment Leadership and Growth Trends
Cell and Gene Therapy CDMO Market Share (%), by Phase, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportPhase Segment Analysis: Pre-clinical (Largest Segment) vs Clinical (Fastest-Growing Segment)
In the cell and gene therapy CDMO market, the pre-clinical segment accounted for the largest share of 62.95% in 2026. Its leading position is supported by the substantial development activity required before cell and gene therapies advance into human trials. CDMOs play an important role during this stage by providing process development, analytical support, manufacturing expertise, and other specialized capabilities needed to establish viable production approaches. Growing reliance on external development partners can further strengthen demand for CDMO services as therapy developers seek specialized capabilities while managing the technical complexity associated with advanced therapeutic modalities.
The clinical segment is expected to register the fastest growth, supported by the increasing progression of cell and gene therapy candidates into clinical development. As programs advance beyond pre-clinical evaluation, developers require more sophisticated manufacturing, quality, regulatory, and process-support capabilities to meet the requirements of clinical-stage development. This transition is likely to increase demand for specialized CDMO partnerships, particularly as therapy developers seek scalable and compliant manufacturing solutions that can support programs through increasingly advanced stages of development.
Product Type Segment Analysis: Cell Therapy (Largest Segment) vs Gene-Modified Cell Therapy (Fastest-Growing Segment)
The cell therapy segment held the largest share of 45.37% in 2026, reflecting the established demand for CDMO services supporting the development and manufacturing of cell-based therapeutic products. The complexity of cell processing, the need for controlled manufacturing environments, and specialized quality requirements encourage developers to work with experienced external manufacturing partners. Continued development of cell-based therapies is therefore supporting demand for outsourced capabilities spanning process development, manufacturing, testing, and related technical services.
Gene-modified cell therapy is anticipated to be the fastest-growing segment as advances in genetic modification expand the potential of cell-based therapeutic approaches. These therapies require specialized capabilities to manage both cellular processing and genetic modification activities, increasing the need for technically sophisticated CDMO support. Growing development activity in this area is expected to encourage greater outsourcing as therapy developers seek access to specialized infrastructure and expertise while addressing the complex manufacturing requirements associated with gene-modified cellular products.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Phase | Pre-clinical, Clinical | Pre-clinical | Clinical |
| Product Type | Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy | Cell Therapy | Gene-Modified Cell Therapy |
| Indication | Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Others | Oncology | Rare Diseases |
Competitive Landscape and Market Positioning
Key companies in the cell and gene therapy CDMO market:
1. Lonza Group AG (Switzerland)
2. Thermo Fisher Scientific Inc. (United States)
3. Catalent Inc. (United States)
4. Samsung Biologics Co. Ltd. (South Korea)
5. WuXi AppTec Co. Ltd. (China)
6. AGC Biologics (Japan)
7. Charles River Laboratories International Inc. (United States)
8. Cytiva (United States)
9. Rentschler Biopharma SE (Germany)
10. Fujifilm Diosynth Biotechnologies (Japan)
Rapid advancements in biologics manufacturing are driving transformation in the cell and gene therapy CDMO market. The cell and gene therapy CDMO market is experiencing strong momentum due to rising demand for scalable, precision-based production capabilities. Strategic collaborations are enabling knowledge sharing and acceleration of manufacturing innovation, while technology adoption in bioprocessing and automation is improving efficiency and reliability. Continuous R&D investments are further enhancing process optimization and supporting next-generation therapeutic development.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Lonza Group AG (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Catalent Inc. (United States) | |||||||
| Samsung Biologics Co. Ltd. (South Korea) | |||||||
| WuXi AppTec Co. Ltd. (China) | |||||||
| AGC Biologics (Japan) | |||||||
| Charles River Laboratories International Inc. (United States) | |||||||
| Cytiva (United States) | |||||||
| Rentschler Biopharma SE (Germany) | |||||||
| Fujifilm Diosynth Biotechnologies (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Minaris Advanced Therapies | Apr-25 | Altaris launched Minaris Advanced Therapies by integrating the operations and assets of Minaris Regenerative Medicine and WuXi Advanced Therapies. This strategic consolidation creates a large-scale, globally integrated CDMO platform, significantly expanding manufacturing capacity and end-to-end service capabilities for cell and gene therapy developers across North America, Europe, and Asia. |
| OXB | Apr-25 | OXB expanded its U.S. manufacturing footprint by acquiring a commercial-scale, FDA-approved viral vector facility in North Carolina from Resilience. This acquisition bolsters the company’s internal capacity to support the increasing demand for lentiviral vectors, further strengthening its role as a key supplier for CAR-T and advanced therapy programs. |
| Artis BioSolutions | Apr-25 | Artis BioSolutions officially launched by acquiring Landmark Bio to establish an integrated manufacturing platform for genetic medicines. This acquisition provides Artis with advanced process development and clinical-scale infrastructure in the Boston area, positioning the firm to offer end-to-end CDMO services aimed at streamlining the development and production of complex cell and gene therapies. |
| OXB | Apr-25 | OXB extended its strategic manufacturing partnership with Bristol Myers Squibb to supply lentiviral vectors for CAR-T therapy production. This agreement underscores the company’s role as a critical supply chain partner in the commercial-stage manufacturing of advanced cell therapies and reinforces its long-term commercial engagement with major biopharmaceutical developers. |
| Quvara Medical | Apr-25 | Quvara Medical launched as a new CDMO following the acquisition and conversion of a former Becton Dickinson manufacturing facility in the U.K. This market entry increases regional outsourced manufacturing capacity for advanced medical products, providing developers with additional infrastructure for cell and gene therapy production and fill-finish services. |
| Matica Biolabs | Apr-25 | Matica Biolabs, a subsidiary of CHA Biotech, signed a manufacturing agreement with TiCARos to support the development and production of solid tumor CAR-T therapies. The partnership enhances the company’s manufacturing pipeline and clinical-stage project portfolio, reflecting a strategic focus on expanding service capabilities within the next-generation immunotherapy production segment. |
| uBriGene Biosciences | Apr-25 | The company launched a new offering of fully characterized induced pluripotent stem cell (iPSC) banks. This development provides a standardized, scalable starting material for regenerative medicine developers, addressing a critical bottleneck in cell therapy development and accelerating research, translational, and clinical-stage workflows for clients. |
| Oxford Biomedica | Mar-25 | The company significantly enhanced its global viral vector manufacturing network through the acquisition of ABL Europe. By integrating ABL’s multi-site infrastructure across the U.K., U.S., and Europe, the firm has strengthened its position as a vertically integrated, global CDMO capable of supporting complex drug product manufacturing and viral vector development. |
| RoslinCT | Mar-25 | RoslinCT entered a strategic manufacturing partnership with Ayrmid Pharma to manage the technology transfer and commercial production of Omisirge®. This collaboration solidifies RoslinCT’s role in the supply chain for FDA-approved cell therapies, demonstrating its capability to handle complex clinical-to-commercial transitions in the hematological malignancy treatment space. |
| Catalent | Jan-25 | Catalent entered a strategic collaboration with Galapagos NV to support a decentralized manufacturing model for CAR-T therapies. By leveraging local manufacturing sites to improve clinical trial logistics, the partnership aims to enhance patient access and accelerate the development cycle of advanced therapies, showcasing a shift in production distribution models. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cell and Gene Therapy CDMO Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Service Type | Process Development, Analytical & Quality Testing, Manufacturing, Fill-Finish & Packaging, Regulatory & Other Support Services |
| Manufacturing Scale | Preclinical & Early-Stage Scale, Clinical-Stage Scale, Commercial Scale |
| Outsourcing Model | Full-Service Outsourcing, Modular/Partial Outsourcing, Technology Transfer & Capacity-Based Outsourcing |
Cell and Gene Therapy CDMO Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Manufacturing Capacity Gap Assessment |
|
| Outsourcing Strategy Evaluation |
|
| Advanced Therapy Commercialization Roadmap |
|
Need a different cut of the data?
Request Custom ResearchHow big is the cell and gene therapy CDMO market?
What is the anticipated CAGR of the cell and gene therapy CDMO industry?
How is the shift from pre-clinical to clinical-stage programs reshaping outsourcing demand in the cell and gene therapy CDMO market?
Why are gene-modified cell therapies accelerating CDMO engagement compared with conventional cell therapy programs?
Why does the Pre-clinical phase lead the cell and gene therapy CDMO market?
Why is Gene-Modified Cell Therapy the fastest-growing product type in the cell and gene therapy CDMO market?
Why is North America the leading region in the cell and gene therapy CDMO market?
What is accelerating market growth in Asia Pacific?
Who are the major participants shaping the cell and gene therapy CDMO landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization